SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-291671
Filing Date
2023-12-08
Accepted
2023-12-08 16:06:02
Documents
13
Period of Report
2023-12-04
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d565852d8k.htm   iXBRL 8-K 28986
  Complete submission text file 0001193125-23-291671.txt   202952

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20231204.xsd EX-101.SCH 3541
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE qncx-20231204_def.xml EX-101.DEF 15779
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20231204_lab.xml EX-101.LAB 25566
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20231204_pre.xml EX-101.PRE 16407
7 EXTRACTED XBRL INSTANCE DOCUMENT d565852d8k_htm.xml XML 7321
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 231475431
SIC: 2836 Biological Products, (No Diagnostic Substances)